A Phase Ⅱ Study Assessing the Safety and Efficacy of PLB1004 in EGFR ex20ins Mutation Patients With Advanced and Metastatic Non-small Cell Lung Cancer(NSCLC)
NCT06015503
·
clinicaltrials.gov ↗
PHASE2
Phase
RECRUITING
Status
157
Enrollment
INDUSTRY
Sponsor class
Conditions
Non-Small-Cell Lung Cancer
Interventions
DRUG:
PLB1004
Sponsor
Avistone Biotechnology Co., Ltd.